Viruses · 2021 · 21 citations · 23 references
Life SciencesImmunologyInfectious DiseasesMolecular VirologyVaccinologyVirologyAntigen DesignVaccine Antigen DesignVaccine Antigen DiscoveryVaccine PlatformsViral VaccinesConserved Epitope DesignCoronavirus VaccinesCytotoxic T Lymphocyte EpitopesEpitope-based Vaccine DesignGenetic Algorithm Based DesignMosaic Antigen DesignRational DesignT-cell Epitopes
With the rapid global spread of the Coronavirus Disease 2019 (COVID-19) pandemic, a safe and effective vaccine against human coronaviruses (HCoVs) is believed to be a top priority in the field of public health. Due to the frequent outbreaks of different HCoVs, the development of a pan-HCoVs vaccine is of great value to biomedical science. The antigen design is a key prerequisite for vaccine efficacy, and we therefore developed a novel antigen with broad coverage based on the genetic algorithm of mosaic strategy. The designed antigen has a potentially broad coverage of conserved cytotoxic T lymphocyte (CTL) epitopes to the greatest extent, including the existing epitopes from all reported HCoV sequences (HCoV-NL63, HCoV-229E, HCoV-OC43, HCoV-HKU1, SARS-CoV, MERS-CoV, and SARS-CoV-2). This novel antigen is expected to induce strong CTL responses with broad coverage by targeting conserved epitopes against multiple coronaviruses.
23
CD-HIT: accelerated for clustering the next-generation sequencing data
LiMin Fu, Beifang Niu, Zhengwei Zhu et al. · Bioinformatics · 2012 · 11.8K citations · Full text
Life Sciences, Bioinformatics, High-performance Computing +12
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Nina Le Bert, Anthony T. Tan, Kamini Kunasegaran et al. · Nature · 2020 · 2.2K citations · Full text
Development of an inactivated vaccine candidate for SARS-CoV-2
Qiang Gao, Linlin Bao, Haiyan Mao et al. · Science · 2020 · 1.5K citations · Full text